Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Compass Pathways (CMPS) added ~20% in the premarket on Tuesday after the U.K.-based biotech announced that its psychedelic ...

LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, ...

This open-label study included 19 patients from clinical sites in Ireland and the United States. The majority of patients were female (68.4%) and the average age was 42 years. The primary endpoint was ...

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

Feb 17 (Reuters) - Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy reduced the severity of symptoms in a late-stage study, sending its shares up nearly 23%. The ...

Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

COMPASS Pathways' CMPS Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TRD) is still nourishing the psychedelics research field, as ...